Answers are grounded in this paper and cite their sources.
Systematic review evaluates mirtazapine’s tolerability in children and adolescents, suggesting potential safety.
Background This systematic review evaluates the tolerability and safety of mirtazapine in children and adolescents and quantitatively synthesizes the outcomes. Methods We searched 4 databases through January 28, 2026, for studies on mirtazapine monotherapy in patients aged ≤19 years. We performed a systematic review incorporating quantitative synthesis to estimate pooled incidences of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and withdrawals due to adverse effects (AEs). Results We included 6 studies (2 randomized controlled trials, 4 non-randomized studies; N = 225). The included RCTs showed a high risk of bias, while all NRSs showed low risk. In NRSs, TEAEs ranged from 34.8% to 75%. Pooled incidences of 53.8% for TEAEs, 33.0% for sedation, and 22.3% for weight gain are mixed for significance and heterogeneity and must be interpreted as preliminary signals. SAEs and withdrawals due to AEs were rarely reported. Conclusions This is the first systematic review of mirtazapine in children and adolescents. This review suggests a tolerable adverse event profile comparable to SSRIs. The small number of subjects prevents definitive interpretation. Clinicians might consider mirtazapine as an off-label option for pediatric patients with sleep and appetite disruptions.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: